

Regimen Reference Order – LEUK – Millennium 3001 (Induction)

ARIA: LEUK – [Millennium 3001 Induction]

LEUK – [Millennium 3001 Induction IT]

Planned Course: Every 28 days for 3 cycles

Indication for Use: Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive (Ph+);
Newly Diagnosed

CVAD: Preferred (VESICANT INVOLVED)

Proceed with treatment if:

Days 1 and 14

- Progress note in ARIA from Leukemia/BMT (L/BMT) clinic confirms to proceed
- ❖ Contact L/BMT Hematologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LEUK – Millennium 3001 (Induction)

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
dexamethasone	<p>If age less than 60 years: 40 mg</p> <p>If age greater than or equal to 60 years: 20 mg</p>	Orally once daily in the morning with food on Days 1 to 4 and Days 11 to 14 (Self-administered at home)
iMAtinib	600 mg	Orally once daily throughout treatment Take with food. Do not crush or chew iMAtinib continues daily after the three cycles of induction are complete (Self-administered at home)
vinCRiStine	1.4 mg/m ² ; maximum dose 2 mg	IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion on Days 1 and 14 <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>

iMAtinib available dosage strengths: 100 mg and 400 mg tablets

Classification: Cytotoxic, Hazardous

Patients will receive triple Intrathecal Therapy on **Days 1 and 14**
(See **Appendix A – Intrathecal Therapy (IT)**)

In the event of an infusion-related hypersensitivity reaction, refer to the ‘**Hypersensitivity Reaction Standing Order**’

REQUIRED MONITORING

All Cycles

Days 1 and 14

- CBC and biochemistry as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- iMAtinib and dexamethasone are cancer therapies in this treatment regimen. Remind patient to take iMAtinib and dexamethasone at home
- Remind patient that iMAtinib continues after the three cycles of induction therapy are complete (as part of consolidation and maintenance) until discontinued by clinic
- Reinforce safe handling precautions of medications, blood and body fluids while on iMAtinib

ADDITIONAL INFORMATION

- vinCRiStine may cause neuropathy
- Support protocol is available for triple Intrathecal Therapy under **Millennium 3001 IT** in the “Leukemia” folder

Appendix A**Intrathecal Therapy (IT) – LEUK – [Millennium 3001 Induction IT]****Proceed with treatment if:****Days 1 and 14**

- **Platelets equal to or greater than $50 \times 10^9/L$**
 - ❖ **Contact L/BMT Hematologist if parameters not met**

Days 1 and 14

Drug	Dose	CCMB Administration Guideline
methotrexate	12 mg	Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic
cytarabine	40 mg	
hydrocortisone sodium succinate	50 mg	

IT is ordered as a separate support regimen to start on Day 1 of Millennium 3001 Induction